PT  - JOURNAL ARTICLE
AU  - Bertrand Moal
AU  - Arthur Orieux
AU  - Thomas Ferté
AU  - Antoine Neuraz
AU  - Gabriel A Brat
AU  - Paul Avillach
AU  - Clara-Lea Bonzel
AU  - Tianxi Cai
AU  - Kelly Cho
AU  - Sébastien Cossin
AU  - Romain Griffier
AU  - David A Hanauer
AU  - Christian Haverkamp
AU  - Yuk-Lam Ho
AU  - Chuan Hong
AU  - Meghan R Hutch
AU  - Jeffrey G Klann
AU  - Trang T Le
AU  - Ne Hooi Will Loh
AU  - Yuan Luo
AU  - Adeline Makoudjou
AU  - Michele Morris
AU  - Danielle L Mowery
AU  - Karen L Olson
AU  - Lav P Patel
AU  - Malarkodi J Samayamuthu
AU  - Fernando J Sanz Vidorreta
AU  - Emily R Schriver
AU  - Petra Schubert
AU  - Guillaume Verdy
AU  - Shyam Visweswaran
AU  - Xuan Wang
AU  - Griffin M Weber
AU  - Zongqi Xia
AU  - William Yuan
AU  - Harrison G Zhang
AU  - Daniela Zöller
AU  - Isaac S Kohane
AU  - The Consortium for Clinical Characterization of COVID-19 by EHR (4CE)
AU  - Alexandre Boyer
AU  - Vianney Jouhet
TI  - Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: international observational federated study based on electronic health records through the 4CE consortium
AID  - 10.1101/2022.03.31.22273257
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.31.22273257
4099  - http://medrxiv.org/content/early/2022/04/01/2022.03.31.22273257.short
4100  - http://medrxiv.org/content/early/2022/04/01/2022.03.31.22273257.full
AB  - Purpose In young adults (18 to 49 years old), investigation of the acute respiratory distress syndrome (ARDS) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been limited. We evaluated the risk factors and outcomes of ARDS following infection with SARS-CoV-2 in a young adult population.Methods A retrospective cohort study was conducted between January 1st, 2020 and February 28th, 2021 using patient-level electronic health records (EHR), across 241 United States hospitals and 43 European hospitals participating in the Consortium for Clinical Characterization of COVID-19 by EHR (4CE). To identify the risk factors associated with ARDS, we compared young patients with and without ARDS through a federated analysis. We further compared the outcomes between young and old patients with ARDS.Results Among the 75,377 hospitalized patients with positive SARS-CoV-2 PCR, 1001 young adults presented with ARDS ( 7.8% of young hospitalized adults). Their mortality rate at 90 days was 16.2% and they presented with a similar complication rate for infection than older adults with ARDS. Peptic ulcer disease, paralysis, obesity, congestive heart failure, valvular disease, diabetes, chronic pulmonary disease and liver disease were associated with a higher risk of ARDS. We described a high prevalence of obesity (53%), hypertension (38%-although not significantly associated with ARDS), and diabetes (32%).Conclusion Trough an innovative method, a large international cohort study of young adults developing ARDS after SARS-CoV-2 infection has been gather. It demonstrated the poor outcomes of this population and associated risk factor.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As previously described(16), each participating HS were responsible for and obtained ethics approval, as needed, from the appropriate ethics committee at their institution. IRB protocols were reviewed and approved at APHP (IRB00011591, Project CSE-20-29_ClinicalCOVID), Bordeaux University Hospital (Registration #CHUBX2020RE0253), Mass General Brigham (IRB#2020P001483), Northwestern University (IRB# STU00212845), University of Kansas (STUDY00146505), University of Freiburg (Application #255/20, Process #210587), and at VA North Atlantic, Southwest, Midwest, Continental, and Pacific (IRB # 3310-x). The research was determined to be exempt at University of Michigan (IRB# HUM00184357), Beth Israel Deaconess Medical Center (IRB# 2020P000565), University of Pittsburgh (STUDY20070095), and University of Pennsylvania (IRB#842813). University of California Los Angeles determined that this study does not need IRB approval because research using limited data sets does not constitute human subjects research.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableAggregated data presented in the study are available from XXXXXSARS-CoV-2severe acute respiratory syndrome coronavirus 2ARDSacute respiratory distress syndromeEHRelectronic health records4CEConsortium for Clinical Characterization of COVID-19 by HERICUintensive care unitHShealthcare systemsICDinternational classification diseases